Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA 2415498 A1 · Owner: Shawar, Ribhi M. · Inventors: Baker, William R.; Ryckman, David M.; Huh, Kay K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Macrolide formulations, such as an erythromycylamine formulation for delivery , by aerosolization are described. The concentrated erythromycylamine formulations contain an amount of erythromycylamine effective to treat infections caused by susceptible bacteria. Unit dose devices having a container containing a formulation of the macrolide antibiotic in a physiologically acceptable carrier are also described. Methods for treatment of pulmonary infections by a formulation (liquid solution suspension, or dry , powder) delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5 µm are also described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 10, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 10, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 10, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.